Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” first quarter ...

Investing.com -- Moody’s Ratings has uplifted the rating of Royalty Pharma plc’s senior unsecured notes from Baa3 to Baa2. The outlook for the company has also been revised, shifting from positive to ...

Shares of Royalty Pharma plc (NASDAQ:RPRX – Get Free Report) have been given a consensus recommendation of “Buy” by the five ratings firms that are covering the company, MarketBeat.com reports.

In its first-quarter 2025 investor letter, Patient Capital Opportunity Equity Strategy highlighted stocks such as Royalty Pharma plc (NASDAQ:RPRX). Royalty Pharma plc (NASDAQ:RPRX) is a buyer of ...

The U.S. Food and Drug Administration (FDA) has approved Ferring Pharmaceuticals’ drug product manufacturing hub in ...

Lisa Thomas, Managing Director and Deputy Head of Global Research at TD Cowen, described markets as "fragile," citing sentiment and presidential influence. She highlighted Royalty Pharma as a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Royalty Pharma is planning the biggest IPO of the year as the market’s appetite for biotech stocks remains strong. The company said in a filing with the US financial regulator that it plans ...